{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:19:42Z","timestamp":1768565982327,"version":"3.49.0"},"reference-count":17,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T00:00:00Z","timestamp":1541376000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infect. Control Hosp. Epidemiol."],"published-print":{"date-parts":[[2019,1]]},"abstract":"Abstract<\/jats:title>Objective<\/jats:title>Point-prevalence surveys for infection or colonization with methicillin-resistant Staphylococcus aureus<\/jats:italic> (MRSA), vancomycin-resistant Enterococcus<\/jats:italic> (VRE), extended-spectrum \u03b2-lactamase (ESBL)-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae (CREs), and for Clostridium difficile<\/jats:italic> infection (CDI) were conducted in Canadian hospitals in 2010 and 2012 to better understanding changes in the epidemiology of antimicrobial-resistant organisms (AROs), which is crucial for public health and care management.<\/jats:p><\/jats:sec>Methods<\/jats:title>A third survey of the same AROs in adult inpatients in Canadian hospitals with \u226550 beds was performed in February 2016. Data on participating hospitals and patient cases were obtained using standard criteria and case definitions. Associations between ARO prevalence and institutional characteristics were assessed using logistic regression models.<\/jats:p><\/jats:sec>Results<\/jats:title>In total, 160 hospitals from 9 of the 10 provinces with 35,018 adult inpatients participated in the survey. Median prevalence per 100 inpatients was 4.1 for MRSA, 0.8 for VRE, 1.1 for CDI, 0.8 for ESBLs, and 0 for CREs. No significant change occurred compared to 2012. CREs were reported from 24 hospitals (15%) in 2016 compared to 10 hospitals (7%) in 2012. Routine universal or targeted admission screening for VRE decreased from 94% in 2010 to 74% in 2016. Targeted screening for MRSA on admission was associated with a lower prevalence of MRSA infection. Large hospitals (>500 beds) had higher prevalences of CDI.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>This survey provides national prevalence rates for AROs in Canadian hospitals. Changes in infection control and prevention policies might lead to changes in the epidemiology of AROs and our capacity to detect them.<\/jats:p><\/jats:sec>","DOI":"10.1017\/ice.2018.279","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T09:32:04Z","timestamp":1541410324000},"page":"53-59","source":"Crossref","is-referenced-by-count":14,"title":["Prevalence of antibiotic-resistant organisms in Canadian Hospitals. Comparison of point-prevalence survey results from 2010, 2012, and 2016"],"prefix":"10.1017","volume":"40","author":[{"given":"Philippe","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire Nour","family":"Abou Chakra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Bush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myrna","family":"Dyck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahir","family":"Hirji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar E.","family":"Larios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"McGeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew E.","family":"Simor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Infection Prevention and Control Canada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2018,11,5]]},"reference":[{"key":"S0899823X18002799_ref14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw741"},{"key":"S0899823X18002799_ref11","volume-title":"Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus","year":"2014"},{"key":"S0899823X18002799_ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.25"},{"key":"S0899823X18002799_ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306801"},{"key":"S0899823X18002799_ref6","unstructured":"Public Health Agency of Canada. Federal Action Plan on Antimicrobial Resistance and Use in Canada. Guelph ON: PHAC; 2015."},{"key":"S0899823X18002799_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.01.024"},{"key":"S0899823X18002799_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2016.02.001"},{"key":"S0899823X18002799_ref16","unstructured":"Centers for Disease Control and Prevention. FAQs About Choosing and Implementing a CRE Definition. Atlanta: CDC; 2015."},{"key":"S0899823X18002799_ref7","unstructured":"House TW . National Action Plan for Combating Antibotic-Resistant Bacteria. Atlanta: CDC; 2015."},{"key":"S0899823X18002799_ref17","unstructured":"Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. Atlanta: CDC; 2013."},{"key":"S0899823X18002799_ref13","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial Resistance surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Solna, Sweden: ECDC; 2017."},{"key":"S0899823X18002799_ref5","unstructured":"CDC\/NHSN. Surveillance Definitions for Specific Types of Infections. Atlanta: CDC; 2015."},{"key":"S0899823X18002799_ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.4114"},{"key":"S0899823X18002799_ref12","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.174"},{"key":"S0899823X18002799_ref4","doi-asserted-by":"publisher","DOI":"10.1086\/670998"},{"key":"S0899823X18002799_ref2","unstructured":"Public Health Agency of Canada. Canadian Antimicrobial Resistance Surveillance System\u2014Report 2016. Guelph ON: PHAC; 2016."},{"key":"S0899823X18002799_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.11.029"}],"container-title":["Infection Control & Hospital Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0899823X18002799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T21:20:05Z","timestamp":1555104005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0899823X18002799\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,5]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0899823X18002799"],"URL":"https:\/\/doi.org\/10.1017\/ice.2018.279","relation":{},"ISSN":["0899-823X","1559-6834"],"issn-type":[{"value":"0899-823X","type":"print"},{"value":"1559-6834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,5]]}}}